Corbus Pharmaceuticals Holdings (CRBP) Shares Outstanding (2013 - 2025)
Corbus Pharmaceuticals Holdings (CRBP) posted quarterly Shares Outstanding (Entity) of $17.6 million for Q4 2025, up 44.6% year-over-year from $12.2 million in Q4 2024, and up 40.5% quarter-over-quarter from $12.5 million in Q3 2025.
Corbus Pharmaceuticals Holdings (CRBP) Shares Outstanding (2013 - 2025) Analysis & Trends
Corbus Pharmaceuticals Holdings' Shares Outstanding (Entity) history runs 13 years deep, the most recent figure standing at $17.6 million for Q4 2025.
- In Q4 2025, Shares Outstanding (Entity) rose 44.6% year-over-year to $17.6 million; the TTM figure through Dec 2025 stood at $17.6 million (up 44.6% YoY), while the FY2025 annual figure was $17.6 million, up 44.6% from the prior year.
- Shares Outstanding (Entity) for Q4 2025 stood at $17.6 million, up from $12.5 million in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $17.6 million in Q4 2025, with the low at $4.2 million in Q1 2021.
- The 5-year median for Shares Outstanding (Entity) is $4.4 million (2023), against an average of $7.5 million.
- The sharpest annual moves came in 2022 and 2024: Shares Outstanding (Entity) fell 0.06% in 2022, then jumped 175.32% in 2024.
- Corbus Pharmaceuticals Holdings' Shares Outstanding (Entity) stood at $4.2 million in 2021, then fell by 0.06% to $4.2 million in 2022, then grew by 6.05% to $4.4 million in 2023, then jumped by 175.32% to $12.2 million in 2024, then soared by 44.6% to $17.6 million in 2025.
- Business Quant data shows CRBP's Shares Outstanding (Entity) at $17.6 million in Q4 2025, $12.5 million in Q3 2025, and $12.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Corbus Pharmaceuticals Holdings | 127.63 Mn | -35.64 Mn | - | 12.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 12.31 Mn |
| Sep 30, 2025 | 12.31 Mn |
| Jun 30, 2025 | 12.24 Mn |
| Mar 31, 2025 | 12.20 Mn |
| Dec 31, 2024 | 10.92 Mn |
| Sep 30, 2024 | 12.01 Mn |
| Jun 30, 2024 | 11.05 Mn |
| Mar 31, 2024 | 8.31 Mn |
| Dec 31, 2023 | 4.33 Mn |
| Sep 30, 2023 | 4.42 Mn |
| Jun 30, 2023 | 4.28 Mn |
| Mar 31, 2023 | 4.18 Mn |
| Dec 31, 2022 | 4.17 Mn |
| Sep 30, 2022 | 4.18 Mn |
| Jun 30, 2022 | 4.17 Mn |
| Mar 31, 2022 | 4.17 Mn |
| Dec 31, 2021 | 4.10 Mn |
| Sep 30, 2021 | 4.17 Mn |
| Jun 30, 2021 | 3.88 Mn |
| Mar 31, 2021 | 3.88 Mn |